Although the evidence and sample sizes of neoadjuvant immunotherapy in patients with UTUC are limited, some immunologic features, such as intratumoral CD8+ T cells or IFN-γ signatures, are considered indicators of responders administered immune checkpoint inhibitor therapy [41]. The gene discussed is CD8A; the disease is renal pelvis/ureter urothelial carcinoma.